eligard 1 month
mundipharma new zealand ltd - leuprorelin acetate 7.5mg (includes 10.2mg leuprorelin acetate to deliver 7.5mg leuprorelin); ; ; leuprorelin acetate 7.5mg (includes 10.6mg leuprorelin acetate to deliver 7.5mg leuprorelin) - injection with diluent - 7.5 mg - active: leuprorelin acetate 7.5mg (includes 10.2mg leuprorelin acetate to deliver 7.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 7.5mg (includes 10.6mg leuprorelin acetate to deliver 7.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.
eligard 3 month
mundipharma new zealand ltd - leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin); ; ; leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) - injection with diluent - 22.5 mg - active: leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.
eligard 4 month
mundipharma new zealand ltd - leuprorelin acetate 30mg (includes 35.8mg leuprorelin acetate to deliver 30mg leuprorelin); ; ; leuprorelin acetate 30mg (includes 37.2mg leuprorelin acetate to deliver 30mg leuprorelin) - injection with diluent - 30 mg - active: leuprorelin acetate 30mg (includes 35.8mg leuprorelin acetate to deliver 30mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 30mg (includes 37.2mg leuprorelin acetate to deliver 30mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.
eligard 6 month
mundipharma new zealand ltd - leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin); ; ; leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) - injection with diluent - 45 mg - active: leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.
prostap 11.25 milligram pdr+solv for susp for inj
takeda uk limited - leuprorelin acetate - pdr+solv for susp for inj - 11.25 milligram - gonadotropin releasing hormone analogues
prostap sr dcs 3.75 milligram pdr+solv for susp for inj
takeda uk limited - leuprorelin acetate - pdr+solv for susp for inj - 3.75 milligram - gonadotropin releasing hormone analogues
lucrin depot for injection pds 30mg
abbvie pte. ltd. - leuprorelin acetate - injection, powder, for solution - 30mg - leuprorelin acetate 30mg
prostap sr dcs 3.75mg powder and solvent for suspension for injection pre-filled syringes
takeda uk ltd - leuprorelin acetate - powder and solvent for suspension for injection - 3.75mg
prostap 3 dcs 11.25mg powder and solvent for suspension for injection pre-filled syringes
takeda uk ltd - leuprorelin acetate - powder and solvent for suspension for injection - 11.25mg
prostap 30 milligram unknown
takeda uk limited - leuprorelin acetate - unknown - 30 milligram - gonadotropin releasing hormone analogues